profit from every $100 of sales.
$0$100
Sonoma Pharmaceuticals
$1.09-6.84% today
-69.2% in 1 year
1-year low $1.011-year high $3.80
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Sonoma Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $12.6 million in 2022 to $14.3 million in 2025, with -$3.46 million of profit last year.
SalesProfit
Sonoma Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Sonoma Pharmaceuticals | No profit yet | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Sonoma Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 13 | 13 | 13 | 14 | |
| 4 | 4 | 5 | 5 | |
| -6 | -5 | -5 | -4 | |
| -6 | -4 | -5 | -4 | |
| -5 | -5 | -5 | -3 | |
| -38.40 | -30.40 | -10.63 | -2.79 | |
| 31.6% | 33.7% | 37.3% | 38.2% | |
| -46.6% | -34.4% | -36.9% | -26.0% | |
| -40.3% | -38.8% | -38.0% | -24.2% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 19 | 16 | 15 | 14 |
| Cash | 7 | 4 | 3 | 5 |
| Total debt | 1 | 1 | 1 | 0 |
| Total liabilities | 10 | 8 | 9 | 9 |
| 9 | 8 | 6 | 4 | |
| 0 | 0 | 0 | 1 | |
| -46.2% | -40.9% | -55.1% | -62.1% | |
| -58.5% | -64.6% | -78.8% | -78.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -4 | -6 | -2 | -0 | |
| 0 | 0 | 0 | 0 | |
| -4 | -6 | -2 | -0 | |
| Dividends paid | – | – | – | – |
| – | – | 0 | 0 | |
| 0 | 1 | 1 | 0 |
Valuation
- –
- –
- –
- 0.6×
- 0.4×
- –
- –
- -3.0%
- -62.7%
- 0.0%
Profitability
- 38.2%
- -26.0%
- -24.2%
- -17.1%
- -28.3%
- -60.6%
- -85.9%
- -24.7%
- -29.4%
- 12.1%
Growth
- +4.2%
- –
- +93.0%
- –
- +57.9%
Financial health
- -1.4×
- 0.19
- 4.8%
- –
- 2.88
- 2.00
- 1.30
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 13%of 963
Bottom 10%of 894
Bottom 27%of 908
Bottom 21%of 991
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Feb 10, 2026 | -0.35 | -0.29 | −20.7% |
| Nov 4, 2025 | -0.13 | -0.31 | +58.1% |
| Aug 7, 2025 | -0.37 | -0.51 | +27.5% |
| Jun 17, 2025 | -0.15 | -0.73 | +79.5% |
| Feb 5, 2025 | -0.59 | -0.80 | +26.3% |
| Nov 7, 2024 | -0.59 | -1.00 | +41.0% |
| Aug 8, 2024 | -1.40 | -0.06 | −2,233.3% |
| Jun 17, 2024 | -1.40 | -3.41 | +58.9% |
News
Is Williams-Sonoma Stock's Winning Streak Skill Or Luck?Yahoo Finance · Oct 22, 2026Williams-Sonoma's stock has soared in a sluggish housing market. Here's how it won over Wall StreetCNBC · Sep 20, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
28No pass
Benjamin Graham
70Pass
Philip Fisher
22No pass
Peter Lynch
34No pass
Joel Greenblatt
0No pass
Charlie Munger
26No pass
Terry Smith
21No pass
Questions about Sonoma Pharmaceuticals
Is Sonoma Pharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Sonoma Pharmaceuticals AI analysis
What does Sonoma Pharmaceuticals do?
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. It is in Drug Manufacturers - Specialty & Generic.
Does Sonoma Pharmaceuticals pay a dividend?
No. Sonoma Pharmaceuticals does not pay a dividend at the moment; in 2025 it returned $1,000 to shareholders by buying back its own shares.
Is Sonoma Pharmaceuticals stock halal?
No. Sonoma Pharmaceuticals does not pass our halal screen: its cash and confirmed interest-bearing investments are 97% of its market value, at or above the 33% limit. How we check
How has Sonoma Pharmaceuticals stock done over the past year?
Down 69.2% over the past twelve months, to $1.09. It traded between $1.01 and $3.80 and is 71.3% below its high.
Who are Sonoma Pharmaceuticals's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Sonoma Pharmaceuticals's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.